← Back to Search

Anti-tumor antibiotic

Oncozene-DEB-TACE for Liver Cancer

Phase 2
Waitlist Available
Led By Muhammad Beg, MD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Child Pugh Score A only
leukocytes ≥ 3,000/mcL (Measurement and Calibration Lab)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up (oncozene-deb-tace): tace 1 day 22-28, tace 2-6 day 22-28, follow up after completion of treatemtent every 4-6 weeks up to 36 weeks.
Awards & highlights

Study Summary

This trial is testing Onconzene Microspheres, a new way to deliver the cancer drug doxorubicin, to treat patients with liver cancer that cannot be removed by surgery.

Eligible Conditions
  • Liver Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~(oncozene-deb-tace): tace 1 day 22-28, tace 2-6 day 22-28, follow up after completion of treatemtent every 4-6 weeks up to 36 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and (oncozene-deb-tace): tace 1 day 22-28, tace 2-6 day 22-28, follow up after completion of treatemtent every 4-6 weeks up to 36 weeks. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response
Secondary outcome measures
Progression

Trial Design

1Treatment groups
Experimental Treatment
Group I: Oncozene-DEB-TACEExperimental Treatment1 Intervention
Screening Visit (procedures should be done within 28 days of treatment day): Study visit assessments will be performed prior to Oncozene-DEB-TACE delivery (except pharmacokinetic blood draw). Labs may be done within 3 days of the procedure. All visits can be completed +/- 10 days of planned visit day Follow up after completion of treatment every 4-6 weeks:

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
1,047 Previous Clinical Trials
1,053,779 Total Patients Enrolled
4 Trials studying Liver Cancer
5,606 Patients Enrolled for Liver Cancer
Muhammad Beg, MDPrincipal InvestigatorUT Southwestern Medical Center
6 Previous Clinical Trials
118 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin
Muhammad Beg 2015. "A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02141906.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top